Typical of our observations is that presented in Figure 5b, where overall survival was lower in patients whose lung squamous cell carcinomas expressed altered levels of CRELD2, with a median survival of 43.9 months relative to those patients expressing unaltered CRELD2 levels, who had a median survival of 61 months. Here, CRELD2 is linked to squamous cell lung carcinoma.